Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro.

Antimicrobial agents and chemotherapy - 1 Jan 2010

Cheng Yao, Tsou Lun K, Cai Jianfeng, Aya Toshihiro, Dutschman Ginger E, Gullen Elizabeth A, Grill Susan P, Chen Annie Pei-Chun, Lindenbach Brett D, Hamilton Andrew D, Cheng Yung-Chi

Abstract excerpt

Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Interferon alpha-2

Share to Macrocyclic Compounds

Share to Quinolines

Share to Replicon

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 19901090
DOI: 10.1128/AAC.01206-09
PMCID: PMC2798527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19901090-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro.PMID 19901090Read ↗

Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.Semantic proximity Read ↗

P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325.Semantic proximity Read ↗

Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.Semantic proximity Read ↗

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.Semantic proximity Read ↗

Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.Semantic proximity Read ↗

Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C.Semantic proximity Read ↗

Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.Semantic proximity Read ↗

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.